Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006257 · ClinicalTrials.gov registry record · Phase 1
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
NCT00006257 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by City of Hope Medical Center. The trial reports 3 study locations across 1 state.
The verdict
NCT00006257, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
Study Summary
RATIONALE: Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SU5416 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining SU5416 and paclitaxel in treating patients who have advanced cancer.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG semaxanib
Study Locations (3)
California
- Cancer Center and Beckman Research Institute, City of Hope - Duarte
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- University of California Davis Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006257
The ClinicalTrials.gov registry entry for NCT00006257 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00006257 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00006257 about?
NCT00006257 is a clinical study titled "SU5416 and Paclitaxel in Treating Patients With Advanced Cancer". RATIONALE: Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SU5416 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to stu...
What is the current status of trial NCT00006257?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-11.
What conditions does trial NCT00006257 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00006257?
The interventions under investigation include: paclitaxel (DRUG), semaxanib (DRUG).
Who is sponsoring clinical trial NCT00006257?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006257 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.